DURECT Corporation Key Opinion Leader Call on Psoriasis Transcript
Good day, and welcome to the Key Opinion Leader Call on Psoriasis hosted by DURECT Corporation. (Operator Instructions) At this time, I would like turn the conference over to Mr. Mike Arenberg, Chief Financial Officer of DURECT Corporation. Please go ahead.
Welcome to our Key Opinion Leader Call on Psoriasis. This is Mike Arenberg, Chief Financial Officer of DURECT Corporation. This call will begin with a presentation by Dr. Howard Maibach on psoriasis, including an overview of the disease, current treatment options and the treatment landscape for psoriasis. This will be followed by a presentation by Jim Brown, DURECT's President and CEO, on our Phase IIa study on psoriasis with DUR-928, followed by a Q&A session.
Before beginning, I would like to remind you of our safe harbor statement. During the course of this call, we may make forward-looking statements regarding DURECT's business and DUR-928. These forward-looking statements involve risks and uncertainties that can cause actual results to differ
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |